Ischemia Reperfusion Injury – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Ischemia Reperfusion Injury – Pipeline Review, H2 2017’, provides an overview of the Ischemia Reperfusion Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury

The report reviews pipeline therapeutics for Ischemia Reperfusion Injury by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Ischemia Reperfusion Injury therapeutics and enlists all their major and minor projects

The report assesses Ischemia Reperfusion Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Angion Biomedica Corp

Biomedica Management Corp

Bolder Biotechnology Inc

Catalyst Biosciences Inc

Conatus Pharmaceuticals Inc

Corline Biomedical AB

Gilead Sciences Inc

Glucox Biotech AB

Hope Pharmaceuticals Inc

Ischemix Inc

Kowa Company Ltd

NovelMed Therapeutics Inc

Omeros Corp

Opsona Therapeutics Ltd

Orexo AB

Pharming Group NV

Prolong Pharmaceuticals LLC

Prothix BV

Reata Pharmaceuticals Inc

Recordati SpA

SBI Pharmaceuticals Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Ischemia Reperfusion Injury - Overview 5

Ischemia Reperfusion Injury - Therapeutics Development 6

Ischemia Reperfusion Injury - Therapeutics Assessment 20

Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development 30

Ischemia Reperfusion Injury - Drug Profiles 40

Ischemia Reperfusion Injury - Dormant Projects 142

Ischemia Reperfusion Injury - Discontinued Products 145

Ischemia Reperfusion Injury - Product Development Milestones 146

Appendix 153

List of Tables

List of Tables

Number of Products under Development for Ischemia Reperfusion Injury, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Ischemia Reperfusion Injury – Pipeline by Angion Biomedica Corp, H2 2017

Ischemia Reperfusion Injury – Pipeline by Biomedica Management Corp, H2 2017

Ischemia Reperfusion Injury – Pipeline by Bolder Biotechnology Inc, H2 2017

Ischemia Reperfusion Injury – Pipeline by Catalyst Biosciences Inc, H2 2017

Ischemia Reperfusion Injury – Pipeline by Conatus Pharmaceuticals Inc, H2 2017

Ischemia Reperfusion Injury – Pipeline by Corline Biomedical AB, H2 2017

Ischemia Reperfusion Injury – Pipeline by Gilead Sciences Inc, H2 2017

Ischemia Reperfusion Injury – Pipeline by Glucox Biotech AB, H2 2017

Ischemia Reperfusion Injury – Pipeline by Hope Pharmaceuticals Inc, H2 2017

Ischemia Reperfusion Injury – Pipeline by Ischemix Inc, H2 2017

Ischemia Reperfusion Injury – Pipeline by Kowa Company Ltd, H2 2017

Ischemia Reperfusion Injury – Pipeline by NovelMed Therapeutics Inc, H2 2017

Ischemia Reperfusion Injury – Pipeline by Omeros Corp, H2 2017

Ischemia Reperfusion Injury – Pipeline by Opsona Therapeutics Ltd, H2 2017

Ischemia Reperfusion Injury – Pipeline by Orexo AB, H2 2017

Ischemia Reperfusion Injury – Pipeline by Pharming Group NV, H2 2017

Ischemia Reperfusion Injury – Pipeline by Prolong Pharmaceuticals LLC, H2 2017

Ischemia Reperfusion Injury – Pipeline by Prothix BV, H2 2017

Ischemia Reperfusion Injury – Pipeline by Reata Pharmaceuticals Inc, H2 2017

Ischemia Reperfusion Injury – Pipeline by Recordati SpA, H2 2017

Ischemia Reperfusion Injury – Pipeline by SBI Pharmaceuticals Co Ltd, H2 2017

Ischemia Reperfusion Injury – Dormant Projects, H2 2017

Ischemia Reperfusion Injury – Dormant Projects, H2 2017 (Contd..1), H2 2017

Ischemia Reperfusion Injury – Dormant Projects, H2 2017 (Contd..2), H2 2017

Ischemia Reperfusion Injury – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Ischemia Reperfusion Injury, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports